Related Experiment Videos
An immunoenzymometric assay for a CA125-like antigen, CA602
H Mochizuki1, I Sato, K Nagoya
1Biosciences Research Laboratory, Mochida Pharmaceutical Co., LTD., Tokyo, Japan.
Journal of Clinical Laboratory Analysis
|January 1, 1992
Summary
A new assay for CA602, a CA125-like antigen, was developed using monoclonal antibodies. This assay shows promise for improving ovarian carcinoma detection when combined with CA54/61 testing.
Area of Science:
- Oncology
- Immunochemistry
- Biomarker Discovery
Background:
- Ovarian carcinoma detection often relies on biomarkers like CA125.
- There is a need for improved diagnostic tools for early and accurate detection of ovarian cancer.
Purpose of the Study:
- To develop and characterize a novel immunoenzymometric assay (IEMA) for a CA125-like antigen, designated CA602.
- To evaluate the potential of CA602 as a biomarker for ovarian carcinoma.
- To explore the combined diagnostic utility of CA602 and CA54/61.
Main Methods:
- Development of an immunoenzymometric assay (IEMA) using five monoclonal antibodies against a human ovarian carcinoma cell line.
- Epitope analysis to understand antibody-antigen interactions.
- Correlation analysis of CA602 levels with CA125 and CA54/61 levels in patient sera.
Main Results:
- A sensitive IEMA for CA602 was successfully developed using antibodies 602-1 and 602-6.
- Serum CA602 levels showed significant correlation with CA125 levels, indicating CA602 is a CA125-like antigen.
- Serum CA602 levels did not correlate with CA54/61 levels.
Conclusions:
- CA602 is a novel CA125-like antigen with potential as a biomarker in ovarian carcinoma.
- Combined assays of CA602 and CA54/61 may enhance the detection rate of ovarian carcinoma.
- Further research is warranted to validate CA602's clinical utility in ovarian cancer diagnostics.